RHYTHM PHARMACEUTICALS, INC.
For the period ended Aug 4, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 4, 2026 · Filed Aug 4, 2026
Use the contents to explore the available documents and sections.
RYTM$112.28+6.9%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Contraindication
Contraindication
Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.